RIL
MLTX icon

Rothschild Investment LLC’s MoonLake Immunotherapeutics MLTX Stock Holding History

Rothschild Investment LLC’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.97K Buy
204
+198
+3,300% +$3.59K ﹤0.01% 2410
2026
Q1 		$112 Buy
6
+5
+500% +$83 ﹤0.01% 3384
2025
Q4 		$13 Buy
+1
New +$12 ﹤0.01% 3362

Other funds holding MLTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rothschild Investment LLC's MLTX Position: Q2 2026 in Review

Rothschild Investment LLC increased its MoonLake Immunotherapeutics (MLTX) stake by 3,300% in Q2 2026, buying an estimated $3.59K and bringing the position to 204 shares worth $3.97K. The position accounts for ﹤0.01% of the portfolio, ranked #2410.

Rothschild Investment LLC first reported a position in MLTX in Q4 2025 and has held it in 3 quarters since. 40 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Rothschild Investment LLC held 204 shares of MoonLake Immunotherapeutics worth $3.97K as of Q2 2026.
  • Rothschild Investment LLC bought 198 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $3.59K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #2410 holding.
  • Rothschild Investment LLC first reported a position in MoonLake Immunotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • 40 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.